ALEXION PHARMACEUTICALS, INC. Insider Trading for February 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALEXION PHARMACEUTICALS, INC. for February 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 174.06 | 2,471 | 430,102 | 4,840 | 7.3 K to 4.8 K (-33.80 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.09 | 20 | 3,142 | 986,696 | 986.7 K to 986.7 K (0.00 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 155.55 | 4,600 | 715,530 | 986,716 | 991.3 K to 986.7 K (-0.46 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Grant | A | 0.00 | 28,040 | 0 | 991,316 | 963.3 K to 991.3 K (+2.91 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 157.64 | 6 | 946 | 13,765 | 13.8 K to 13.8 K (-0.04 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 155.55 | 1,000 | 155,550 | 13,771 | 14.8 K to 13.8 K (-6.77 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Grant | A | 0.00 | 6,068 | 0 | 14,771 | 8.7 K to 14.8 K (+69.72 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Sell | S | 158.69 | 8 | 1,270 | 19,670 | 19.7 K to 19.7 K (-0.04 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Sell | S | 155.55 | 1,090 | 169,550 | 19,678 | 20.8 K to 19.7 K (-5.25 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Grant | A | 0.00 | 6,068 | 0 | 20,768 | 14.7 K to 20.8 K (+41.28 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 93.83 | 3,800 | 356,554 | 0 | |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 167.31 | 1,635 | 273,552 | 101,308 | 102.9 K to 101.3 K (-1.59 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.51 | 20 | 3,150 | 102,943 | 103 K to 102.9 K (-0.02 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.55 | 1,600 | 248,880 | 102,963 | 104.6 K to 103 K (-1.53 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Grant | A | 0.00 | 9,745 | 0 | 104,563 | 94.8 K to 104.6 K (+10.28 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.11 | 3,800 | 589,418 | 94,818 | 98.6 K to 94.8 K (-3.85 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 93.83 | 3,800 | 356,554 | 98,618 | 94.8 K to 98.6 K (+4.01 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 158.05 | 10 | 1,581 | 113,965 | 114 K to 114 K (-0.01 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 156.95 | 10 | 1,570 | 113,965 | 114 K to 114 K (-0.01 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 155.55 | 1,600 | 248,880 | 113,975 | 115.6 K to 114 K (-1.38 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,745 | 0 | 115,575 | 105.8 K to 115.6 K (+9.21 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Sell | S | 158.56 | 16 | 2,537 | 22,232 | 22.2 K to 22.2 K (-0.07 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Sell | S | 155.55 | 1,020 | 158,661 | 22,248 | 23.3 K to 22.2 K (-4.38 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Grant | A | 0.00 | 6,068 | 0 | 23,268 | 17.2 K to 23.3 K (+35.28 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 157.47 | 20 | 3,149 | 137,900 | 137.9 K to 137.9 K (-0.01 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 155.55 | 1,600 | 248,880 | 137,920 | 139.5 K to 137.9 K (-1.15 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 9,745 | 0 | 139,520 | 129.8 K to 139.5 K (+7.51 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | M | 4.93 | 30,000 | 147,900 | 0 | |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Sell | S | 159.00 | 30,000 | 4,770,000 | 179,217 | 209.2 K to 179.2 K (-14.34 %) |
| Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Buy | M | 4.93 | 30,000 | 147,900 | 209,217 | 179.2 K to 209.2 K (+16.74 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 93.83 | 3,800 | 356,554 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 78.88 | 10,813 | 852,929 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 42.66 | 6,250 | 266,625 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 22.90 | 7,876 | 180,360 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.00 | 29,637 | 4,593,735 | 94,818 | 124.5 K to 94.8 K (-23.81 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 93.83 | 3,800 | 356,554 | 124,455 | 120.7 K to 124.5 K (+3.15 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 78.88 | 10,813 | 852,929 | 120,655 | 109.8 K to 120.7 K (+9.84 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 42.66 | 6,250 | 266,625 | 109,842 | 103.6 K to 109.8 K (+6.03 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 22.90 | 7,876 | 180,360 | 103,592 | 95.7 K to 103.6 K (+8.23 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.10 | 3,300 | 518,430 | 95,716 | 99 K to 95.7 K (-3.33 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 153.63 | 3,200 | 491,616 | 99,016 | 102.2 K to 99 K (-3.13 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.14 | 852 | 133,883 | 102,216 | 103.1 K to 102.2 K (-0.83 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 10.84 | 20,000 | 216,800 | 10,000 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 18.08 | 30,000 | 542,400 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 16.83 | 12,276 | 206,605 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 26.64 | 7,932 | 211,308 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 49.43 | 5,572 | 275,424 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 88.40 | 3,237 | 286,151 | 0 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 96.35 | 1,712 | 164,951 | 1,713 | |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 159.01 | 13,501 | 2,146,794 | 29,456 | 43 K to 29.5 K (-31.43 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 158.41 | 30,222 | 4,787,467 | 42,957 | 73.2 K to 43 K (-41.30 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 157.35 | 12,322 | 1,938,867 | 73,179 | 85.5 K to 73.2 K (-14.41 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 156.24 | 9,664 | 1,509,903 | 85,501 | 95.2 K to 85.5 K (-10.15 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 155.23 | 15,020 | 2,331,555 | 95,165 | 110.2 K to 95.2 K (-13.63 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 10.84 | 20,000 | 216,800 | 110,185 | 90.2 K to 110.2 K (+22.18 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 18.01 | 30,000 | 540,300 | 90,185 | 60.2 K to 90.2 K (+49.85 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 16.83 | 12,276 | 206,605 | 60,185 | 47.9 K to 60.2 K (+25.62 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 26.64 | 7,932 | 211,308 | 47,909 | 40 K to 47.9 K (+19.84 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 49.43 | 5,572 | 275,424 | 39,977 | 34.4 K to 40 K (+16.20 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 88.40 | 3,237 | 286,151 | 34,405 | 31.2 K to 34.4 K (+10.39 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 96.35 | 1,712 | 164,951 | 31,168 | 29.5 K to 31.2 K (+5.81 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 153.63 | 2,700 | 414,801 | 129,775 | 132.5 K to 129.8 K (-2.04 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 157.14 | 852 | 133,883 | 132,475 | 133.3 K to 132.5 K (-0.64 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 157.09 | 3,000 | 471,270 | 58,574 | 61.6 K to 58.6 K (-4.87 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 155.91 | 13,912 | 2,169,020 | 61,574 | 75.5 K to 61.6 K (-18.43 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 154.95 | 10,662 | 1,652,077 | 75,486 | 86.1 K to 75.5 K (-12.38 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 154.02 | 12,426 | 1,913,853 | 86,148 | 98.6 K to 86.1 K (-12.61 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 153.63 | 2,390 | 367,176 | 105,830 | 108.2 K to 105.8 K (-2.21 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 157.14 | 729 | 114,555 | 108,220 | 108.9 K to 108.2 K (-0.67 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 153.63 | 760 | 116,759 | 8,703 | 9.5 K to 8.7 K (-8.03 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 153.63 | 8,870 | 1,362,698 | 963,276 | 972.1 K to 963.3 K (-0.91 %) |
| Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.14 | 2,920 | 458,849 | 972,146 | 975.1 K to 972.1 K (-0.30 %) |